<DOC>
	<DOC>NCT00051116</DOC>
	<brief_summary>To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.</brief_summary>
	<brief_title>A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>History of histologically documented multiple myeloma with relapsed or resistant disease Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. Signed written informed consent and willingness to meet followup schedule and study procedure obligations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Revimid</keyword>
	<keyword>CC5013</keyword>
	<keyword>CC-5013</keyword>
</DOC>